Novo Nordisk stock steady as China accepts oral Wegovy filing
Published on 08/27/2026 at 06:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (ISIN DK0062498333) stock is trading close to its current analyst target as of August 26, 2026, while China’s drug regulator has accepted the company’s marketing application for the oral version of its Wegovy weight-loss treatment, adding a fresh regulatory catalyst to the obesity franchise.
Analyst targets and consensus frame valuation
Market data compiled on August 26, 2026 show Novo Nordisk shares closing at DKK304.95 on Nasdaq Copenhagen, marking a decline of 0.93% on the day and leaving the stock down 6.24% year-to-date but still up 1.84% compared with five sessions earlier. This recent close stands just 1.92% below a reported average analyst price target of DKK310.82, indicating that the stock is already valued close to where consensus expects it to trade in the near term. At the same time, one noted price objective of DKK275 for the shares now implies downside of roughly 10% from the latest close, highlighting a more cautious stance among some analysts.
Per a consensus overview updated on August 27, 2026, the average recommendation on Novo Nordisk is described as “hold,” with 25 analysts contributing to that view and the same DKK304.95 close used as the reference price. With the average target at DKK310.82 and the hold stance prevailing, the market picture is one of a company whose strong fundamentals and pipeline are recognized, but where investors are debating whether current valuation fully captures growth from obesity and diabetes therapies.
Guidance and earnings expectations point to slower growth
While Novo Nordisk continues to benefit from expanding demand for GLP-1-based obesity and diabetes treatments, the most recent full-year guidance for 2026, reiterated after the first and second quarters of the year, signals a more moderate financial trajectory. In its outlook for 2026, the company expects adjusted sales and operating profit to decline between 0% and 6% at constant exchange rates compared with the prior year. Consensus projections for 2026 sales mirror this cautious tone, with a forecast year-over-year decline of 3.60%, while earnings per share are projected to fall 13.89% over the same period.
These figures represent a step down from the rapid expansion seen in earlier years of the GLP-1 launch cycle, and they help explain why the prevailing analyst stance is not more aggressive despite strong product momentum. At the same time, earnings estimates for 2026 have been revised upward during the last 30 days, and projections for 2027 have also improved, suggesting that the latest operating trends and pipeline updates are modestly better than previously feared. For long-term investors, the key question is how quickly oral formulations and new indications can offset the expected normalization in growth rates visible in the 2026 guidance.
Regulatory momentum in China for oral Wegovy
A major operational milestone emerged on August 27, 2026, when China’s drug regulator formally accepted Novo Nordisk’s marketing application for the oral version of its Wegovy weight-loss drug. This acceptance means the dossier for the oral formulation is now under regulatory review, a key step toward potential approval in one of the world’s largest obesity and diabetes markets. The filing reflects Novo Nordisk’s strategy to complement injectable GLP-1 therapies with an oral option that may appeal to a broader population of patients and physicians.
Local data from China’s drug evaluation center on August 27, 2026 show that the formal acceptance covers oral semaglutide tablets, with a specific application number recorded for the submission. This confirms that the company’s obesity portfolio is progressing not only in Western markets but also in major emerging economies. If eventually approved and launched, oral Wegovy in China could help support revenue and profit trends beyond the cautious 2026 guidance, particularly in later years as uptake scales across the country’s large overweight and obese population.
Recent earnings and capital allocation context
In its second-quarter 2026 report, Novo Nordisk delivered increased adjusted profits and raised its full-year forecast, supported by strong adoption of oral Wegovy and sustained demand for GLP-1 therapies across obesity and diabetes indications. Alongside the upgraded forecast, the company accelerated its share repurchase program, committing DKK15 billion to buybacks and having already acquired 29 million B shares for DKK8.39 billion by the time of the report. The board also approved a dividend of $0.58 per share, with the ex-dividend date set for August 17, 2026, underscoring a continued focus on returning capital to shareholders.
These actions position Novo Nordisk as both a growth and income story, even as headline guidance for 2026 points to a pause in top-line and earnings expansion. The combination of an upgraded forecast relative to earlier expectations, a substantial buyback plan and a cash dividend suggests management remains confident in the durability of demand for GLP-1 therapies. For investors, the interplay between rising capital returns and slower reported growth is central to the valuation debate currently encapsulated in the hold-rated analyst consensus and near-target share price.
Technical picture from secondary listings
Outside the company’s primary Copenhagen listing, data for Novo Nordisk’s secondary trading line on the German Tradegate platform show a recent close of EUR40.50 for the shares, reflecting a 2.83% decline on the day while still leaving the stock up 5.52% since the start of 2026 and down 5.38% over the trailing year. This pattern is consistent with the DKK-based quote: modest gains year-to-date despite some pullback and volatility around earnings updates and guidance revisions.
Technical commentary on the US-listed NVO line indicates that the stock has lately faced selling pressure, with a single session decline of 2.12% accompanied by increased intraday volatility of 2.31%. Momentum indicators such as MACD have delivered sell signals even as the share price remained above key moving averages, painting a picture of a name where long-term trend support is intact but short-term sentiment is cautious. For investors tracking chart levels, immediate resistance has been identified around $47.90, with notable support around $47.56; moves through either threshold are being watched to gauge the next leg of the trend.
Obesity and diabetes franchise built on Wegovy
The company’s growth story is anchored in its GLP-1-based obesity and diabetes portfolio, with Wegovy as a flagship brand. Wegovy is a semaglutide-based treatment initially launched in injectable form for chronic weight management in adults, targeting patients with obesity or overweight who have weight-related comorbidities. The drug works by mimicking the action of the GLP-1 hormone to help regulate appetite and calorie intake, leading to clinically meaningful weight loss when combined with lifestyle interventions.
Over the past several quarters, strong real-world uptake of Wegovy has supported revenue growth and contributed to Novo Nordisk’s ability to raise its 2026 forecast despite the more cautious guidance band. The recent push to develop and file an oral version of Wegovy, including the application accepted by China’s regulator on August 27, 2026, illustrates an effort to expand access and convenience for patients who prefer pills to injections. Oral formulations may also allow for broader penetration into primary care settings, raising the long-term addressable market for GLP-1 obesity therapies.
Closing view and latest price context
As of the close on August 26, 2026, Novo Nordisk shares traded at DKK304.95 on Nasdaq Copenhagen, with the price sitting just below the average analyst target of DKK310.82 and reflecting a modest decline during the session. The combination of a cautious 2026 guidance, upward-trending earnings estimates, major regulatory steps such as China’s acceptance of the oral Wegovy application and active capital returns through buybacks and dividends gives investors a multi-layered picture: a mature growth story where pipeline and geographic expansion must offset a slower reported growth profile.
Read more
Further coverage of Novo Nordisk stock on European markets
Fact box
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NOVO-B
Exchange: Nasdaq Copenhagen
Price (as of August 26, 2026, 5:20 p.m. local time): DKK304.95
Sector / Industry: Health care / Pharmaceuticals
Index membership: OMX Copenhagen 25
